Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease (ICONIC)
Immune Checkpoint Inhibitors and Carbon iON Radiotherapy In Solid Cancers With Stable Disease
Sponsor: CNAO National Center of Oncological Hadrontherapy
Listed as NCT05229614, this PHASE2 trial focuses on Head and Neck Squamous Cell Carcinoma and Melanoma and remains actively recruiting participants. Sponsored by CNAO National Center of Oncological Hadrontherapy, it has been updated 8 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Study Description(click to expand)This is a multicenter, open label, non-randomized phase II clinical trial aiming to assess the feasibility and the clinical activity of adding CIRT to ICIs in cancer patients that have obtained a disease stability (SD) with pembrolizumab administered as per standard of care. At study entry, hypofractionated CIRT will be delivered to one measurable lesion previously untreated with local approaches.CIRT will be performed at Fondazione CNAO, Pavia
This is a multicenter, open label, non-randomized phase II clinical trial aiming to assess the feasibility and the clinical activity of adding CIRT to ICIs in cancer patients that have obtained a disease stability (SD) with pembrolizumab administered as per standard of care. At study entry, hypofractionated CIRT will be delivered to one measurable lesion previously untreated with local approaches.CIRT will be performed at Fondazione CNAO, Pavia
Status Flow
Change History
8 versions recorded-
Jan 2026 — Present [monthly]
Recruiting PHASE2
-
Sep 2025 — Present [monthly]
Recruiting PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jun 2023 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 3 earlier versions
-
Mar 2023 — Jun 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2022 — Mar 2023 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- CNAO National Center of Oncological Hadrontherapy
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
- Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
- GSI Helmholtzzentrum für Schwerionenforschung GmbH, Darmstadt, Germany
For direct contact, visit the study record on ClinicalTrials.gov .